MX2012001298A - Acido r-7-(3-aminometil-4-metoxiimino-3-metil-pirrolidin-1-il)-1-c iclopropil-6-fluoro-4-oxo-1,4-dihidro-[1,8]naftiridin-3-carboxili co y sal de acido l-aspartico, proceso para la preparacion de los mismos y composicion farmaceutica que comprende los mismos para antimicrobiano. - Google Patents
Acido r-7-(3-aminometil-4-metoxiimino-3-metil-pirrolidin-1-il)-1-c iclopropil-6-fluoro-4-oxo-1,4-dihidro-[1,8]naftiridin-3-carboxili co y sal de acido l-aspartico, proceso para la preparacion de los mismos y composicion farmaceutica que comprende los mismos para antimicrobiano.Info
- Publication number
- MX2012001298A MX2012001298A MX2012001298A MX2012001298A MX2012001298A MX 2012001298 A MX2012001298 A MX 2012001298A MX 2012001298 A MX2012001298 A MX 2012001298A MX 2012001298 A MX2012001298 A MX 2012001298A MX 2012001298 A MX2012001298 A MX 2012001298A
- Authority
- MX
- Mexico
- Prior art keywords
- yclopropyl
- methoxyimino
- naphthyridine
- pyrrolidin
- aminomethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a ácido R-7-(3-aminometil-4-metox iimino-3-metil-pirrolidin-1-il)-1-ciclopropil-6-fluoro-4-oxo-1,4- dihidro-[1,8] naftiridin-3-carboxílico y sal de ácido L-aspártico, procesos para la preparación de los mismos y composiciones farmacéuticas que comprenden los mismos para antimicrobianos. Debido a que el ácido R-7-(3-aminometil-4-metoxii mino-3-metil-pirrolidin1-il)-1-ciclopropil-6-fluoro-4-oxo-1,4-dih idro-[l,8]naftiridin-3-carboxílico y sal de ácido L-aspártico es más soluble y menos tóxico y tiene menos efectos secundarios como un agente antimicrobiano que el clorhidrato y las otras sales (D-aspartato y fosfato) convencionalmente usadas, la sal puede ser útil para administración oral e inyectable.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090068396A KR101468659B1 (ko) | 2009-07-27 | 2009-07-27 | R-7-(3-아미노메틸-4-메톡시이미노-3-메틸-피롤리딘-1-일)-1-시클로프로필-6-플루오로-4-옥소-1,4-디히드로-[1,8]나프티리딘-3-카르복실산 l-아스파르트산염, 이의 제조방법 및 이를 포함하는 항균용 약학적 조성물 |
PCT/KR2010/004938 WO2011013992A2 (en) | 2009-07-27 | 2010-07-27 | R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and l-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012001298A true MX2012001298A (es) | 2012-02-28 |
Family
ID=43529859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012001298A MX2012001298A (es) | 2009-07-27 | 2010-07-27 | Acido r-7-(3-aminometil-4-metoxiimino-3-metil-pirrolidin-1-il)-1-c iclopropil-6-fluoro-4-oxo-1,4-dihidro-[1,8]naftiridin-3-carboxili co y sal de acido l-aspartico, proceso para la preparacion de los mismos y composicion farmaceutica que comprende los mismos para antimicrobiano. |
Country Status (10)
Country | Link |
---|---|
US (5) | US8664240B2 (es) |
EP (1) | EP2459550B1 (es) |
JP (1) | JP5357335B2 (es) |
KR (1) | KR101468659B1 (es) |
CN (1) | CN102574840B (es) |
AU (1) | AU2010277947B2 (es) |
BR (1) | BR112012001897A2 (es) |
CA (1) | CA2768290C (es) |
MX (1) | MX2012001298A (es) |
WO (1) | WO2011013992A2 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101468659B1 (ko) | 2009-07-27 | 2014-12-05 | 주식회사 아리바이오 | R-7-(3-아미노메틸-4-메톡시이미노-3-메틸-피롤리딘-1-일)-1-시클로프로필-6-플루오로-4-옥소-1,4-디히드로-[1,8]나프티리딘-3-카르복실산 l-아스파르트산염, 이의 제조방법 및 이를 포함하는 항균용 약학적 조성물 |
US10573202B2 (en) * | 2016-09-09 | 2020-02-25 | R.R. Donnelley & Sons Company | Self-erectable display with free floating stop and method for forming the same |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA824096B (en) * | 1981-06-11 | 1983-04-27 | Warner Lambert Co | Salts of antimicrobial naphthyridine and quinoline compounds |
KR0174373B1 (ko) * | 1995-08-03 | 1999-02-18 | 성재갑 | 7-(4-아미노메틸-4-알킬-3-알킬옥심)피롤리딘 치환체를 갖는 신규 퀴놀린 카르복실산 유도체 및 그의 제조방법 |
KR20010029698A (ko) * | 1999-05-20 | 2001-04-06 | 황규언 | 광학활성을 유발하는 7-피롤리딘 치환체를 갖는광학활성의 퀴놀린 카르복실산 유도체 및 그의 제조방법 |
CN1142164C (zh) * | 1999-05-20 | 2004-03-17 | 同和药品工业株式会社 | 具有能产生旋光活性的7-吡咯烷取代基的旋光活性喹啉羧酸衍生物及其制备方法 |
WO2008127060A1 (en) * | 2007-04-13 | 2008-10-23 | Dong Wha Pharmaceutical Co. Ltd. | Aspartate of 1-cyclopropyl-6-fluoro-7-(8-methoxyimino-2,6-diaza- spiro[3.4]oct-6-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid, method for preparing the same, and antimicrobial pharmaceutical composition comprising the same |
WO2009032843A2 (en) * | 2007-09-06 | 2009-03-12 | Auspex Pharmaceuticals, Inc. | Deuterated ethambutols and their use |
KR101468659B1 (ko) | 2009-07-27 | 2014-12-05 | 주식회사 아리바이오 | R-7-(3-아미노메틸-4-메톡시이미노-3-메틸-피롤리딘-1-일)-1-시클로프로필-6-플루오로-4-옥소-1,4-디히드로-[1,8]나프티리딘-3-카르복실산 l-아스파르트산염, 이의 제조방법 및 이를 포함하는 항균용 약학적 조성물 |
-
2009
- 2009-07-27 KR KR1020090068396A patent/KR101468659B1/ko active IP Right Grant
-
2010
- 2010-07-27 US US13/387,080 patent/US8664240B2/en active Active
- 2010-07-27 MX MX2012001298A patent/MX2012001298A/es active IP Right Grant
- 2010-07-27 EP EP10804705.1A patent/EP2459550B1/en active Active
- 2010-07-27 CN CN201080033220.4A patent/CN102574840B/zh active Active
- 2010-07-27 AU AU2010277947A patent/AU2010277947B2/en not_active Ceased
- 2010-07-27 JP JP2012521587A patent/JP5357335B2/ja active Active
- 2010-07-27 CA CA2768290A patent/CA2768290C/en not_active Expired - Fee Related
- 2010-07-27 BR BR112012001897A patent/BR112012001897A2/pt active Search and Examination
- 2010-07-27 WO PCT/KR2010/004938 patent/WO2011013992A2/en active Application Filing
-
2014
- 2014-01-14 US US14/155,249 patent/US8952164B2/en active Active
- 2014-12-18 US US14/574,935 patent/US9150576B2/en active Active
-
2015
- 2015-09-03 US US14/845,143 patent/US9452158B2/en active Active
-
2016
- 2016-08-25 US US15/247,686 patent/US9751840B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9150576B2 (en) | 2015-10-06 |
JP2013500251A (ja) | 2013-01-07 |
AU2010277947B2 (en) | 2013-05-16 |
EP2459550A4 (en) | 2013-01-02 |
US20140128610A1 (en) | 2014-05-08 |
US9452158B2 (en) | 2016-09-27 |
CN102574840A (zh) | 2012-07-11 |
US20150374674A1 (en) | 2015-12-31 |
BR112012001897A2 (pt) | 2016-03-15 |
EP2459550A2 (en) | 2012-06-06 |
CN102574840B (zh) | 2014-05-28 |
EP2459550B1 (en) | 2013-10-09 |
US20160362377A1 (en) | 2016-12-15 |
WO2011013992A2 (en) | 2011-02-03 |
KR101468659B1 (ko) | 2014-12-05 |
US20120130075A1 (en) | 2012-05-24 |
US20150105558A1 (en) | 2015-04-16 |
KR20110010988A (ko) | 2011-02-08 |
CA2768290A1 (en) | 2011-02-03 |
WO2011013992A3 (en) | 2011-06-30 |
CA2768290C (en) | 2014-05-06 |
JP5357335B2 (ja) | 2013-12-04 |
US9751840B2 (en) | 2017-09-05 |
US8952164B2 (en) | 2015-02-10 |
US8664240B2 (en) | 2014-03-04 |
AU2010277947A1 (en) | 2012-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008057802A3 (en) | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same | |
MX2011012122A (es) | Derivados de tiofeno. | |
WO2010065709A3 (en) | Hydroxamic acid derivatives, preparation and therapeutic uses thereof | |
WO2007133637A3 (en) | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | |
NZ597260A (en) | Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone | |
WO2010136474A3 (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
EP3492069A3 (en) | Pharmaceutical compositions | |
WO2006077025A3 (en) | Morpholines as 5ht2c agonists | |
MX2008016134A (es) | Derivados de fenol para el tratamiento de enfermedades respiratorias. | |
IL198314A (en) | History of Quinuclidine of (hetero) Acrylic Cyclohepethecarboxylic Acid, Process of Preparation, Medicinal Preparations Containing Them and Use of Drug Preparation for Treatment | |
WO2008121348A8 (en) | Peripheral opioid receptor antagonists and uses thereof | |
UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
WO2007100758A3 (en) | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | |
UA96622C2 (ru) | Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования | |
SI1742927T1 (sl) | Derivati butanojske kisline, postopki za pripravo le-teh, farmacevtski sestavki, ki jih vsebujejo in terapevtske uporabe le-teh | |
ZA201003380B (en) | Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and methhod for the preparation thereof | |
UA93355C2 (ru) | Композиция субероиланилид-гидроксаминовой кислоты и способы ee получения | |
EP2212325A4 (en) | 2-ARYLMETHYLAZETIDINCARBAPENEM-3-CARBOXYLENE DERTERIVATE OR SALT, METHOD FOR THE PRODUCTION THEREOF AND THEREOF COMPRISING PHARMACEUTICAL COMPOSITION | |
HRP20060079A2 (en) | Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate | |
MX2010003594A (es) | Formas cristalinas de sal sodica de dmxaa. | |
GEP20125526B (en) | Drug active in neuropathic pain | |
MX2009011063A (es) | Aspartato de acido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-dia za-espiro[3.4]oct-6-il)-4-oxo-1,4-dihidro-[1,8]naftiridin-3-carbo xilico, metodo para preparar el mismo y composicion farmaceutica antimicrobiana que comprende el mismo. | |
MX2012001298A (es) | Acido r-7-(3-aminometil-4-metoxiimino-3-metil-pirrolidin-1-il)-1-c iclopropil-6-fluoro-4-oxo-1,4-dihidro-[1,8]naftiridin-3-carboxili co y sal de acido l-aspartico, proceso para la preparacion de los mismos y composicion farmaceutica que comprende los mismos para antimicrobiano. | |
NZ591837A (en) | Amino acid derivative | |
HK1123986A1 (en) | Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |